Table 4.
Associated factors for the treatment failure
| Variable | Cut-off | AUC | Univariable analysis | Multivariable analysis | ||
|---|---|---|---|---|---|---|
| OR (95% CI) | P-value | OR (95% CI) | P-value | |||
| BCR-ABL>10% after 6 months of treatment | ||||||
| RBC, ×1012/L | ≤4.29 | 0.6166 | 3.73 (0.96–14.51) | 0.057 | – | – |
| NRBC, ×109/L | ≥0.003 | 0.6006 | 8.84 (1.71–45.65) | 0.009 | 6.49 (1.09–39.33) | 0.042 |
| BASO, % | ≥0.6 | 0.5816 | 3.16 (1.12–8.87) | 0.029 | – | – |
| Sodium, mmol/L | ≤138.9 | 0.5913 | 2.42 (0.98–6.45) | 0.051 | – | – |
| Chloride, mmol/L | ≤108.1 | 0.6481 | 4.37 (1.29–14.77) | 0.018 | – | – |
| BCR-ABL>1% after 12 months of treatment | ||||||
| RBC, ×1012/L | ≤4.01 | 0.6517 | 5.78 (1.42–23.44) | 0.014 | 7.09 (1.29–38.84) | 0.024 |
| NRBC, ×109/L | ≥0.003 | 0.6977 | 4.92 (1.55–15.64) | 0.007 | 6.73 (1.69–26.76) | 0.007 |
| Potassium, mmol/L | ≥3.62 | 0.5989 | 2.54 (0.87–7.36) | 0.086 | – | – |
| Chloride, mmol/L | ≤104.7 | 0.5672 | 3.43 (0.81–14.53) | 0.095 | – | – |
| BCR-ABL>0.1% after 18 months of treatment | ||||||
| RBC, ×1012/L | ≤4.01 | 0.6294 | 3.10 (1.17–8.24) | 0.023 | 4.11 (1.28–13.20) | 0.018 |
| NRBC, ×109/L | ≥0.003 | 0.6690 | 6.00 (1.59–18.10) | 0.007 | 5.96 (1.54–21.71) | 0.009 |
| BASO, % | ≥0.8 | 0.6183 | 3.08 (0.99–9.66) | 0.051 | – | – |
| Sodium, mmol/L | ≤139.8 | 0.6218 | 3.67 (1.31–10.24) | 0.013 | – | – |
Abbreviations: RBC, red blood cells; WBC, white blood cells; BASO, basophils; NRBC, nucleated red blood cells; PLT, platelets; AUC, area under the ROC curve; OR, odds ratio.